Aripiprazole | CARLAT PUBLISHING

RESEARCH UPDATE

Aripiprazole-Related Psychotic Exacerbations

January 1, 2023

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

This study identifies a common clinical scenario where aripiprazole may trigger psychotic symptoms.

Aripiprazole in Depression: The Right Dose

September 25, 2022

Richard Moldawsky, MD

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dosing recommendations for aripiprazole vary widely in depression, from 2 mg to 15 mg, but this meta-analysis finds a sweet spot in the lower range.

EXPERT Q&A

The Schizophrenia-OCD Overlap

September 28, 2021

Michael Poyurovsky, MD

Michael Poyurovsky, MD

Ma’ale HaCarmel Mental Health Center, Tirat Carmel, Israel; Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. Dr. Poyurovsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

OCD and schizophrenia often overlap, but treatment of this comorbidity is risky terrain. Dr. Poyurovsky explains when antidepressants should be avoided and details which antipsychotics are more likely to exacerbate OCD and which ones are more likely to help it.

Medications to Rapidly Treat Psychotic Agitation

September 13, 2021

Victoria Hendrick, MD. and Daniel Carlat, MD

Victoria Hendrick, MD. Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report.

Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How do you choose medications to calm an acutely psychotic and agitated patient? We'll tell you which ones are the safest and most effective.

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

July 14, 2021

Farah Khorassani, PharmD. Clinical Assistant

Farah Khorassani, PharmD. Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY. Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With so many weight loss medications on the market, it’s hard to know which to choose. Dr. Khorassani tells us everything we need to know to about selecting and prescribing these agents. Also, she gives us additional tips for managing antipsychotic-induced weight gain.

Weight Gain and Metabolic Side Effects

July 14, 2021

Stephen Marder, MD

Stephen Marder, MD

Daniel X. Freedman Professor of Psychiatry. Vice Chair for Education, Semel Institute for Neuroscience at UCLA. Director, VA VISN 22 Mental Illness Research, Education, and Clinical Center, San Diego, CA.

Dr. Marder has disclosed no relevant financial or other interests in any commercial companies pertaining to educational activity.

Dr. Steve Marder describes interventions to minimize patients’ antipsychotic-induced weight gain and insulin resistance.

Hyperprolactinemia: Effective Treatment With Aripiprazole

May 21, 2021

Christina Guest, MD

Christina Guest, MD Dr. Guest has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Many antipsychotic medications produce hyperprolactinemia, leading to breast enlargement in men and missed menstrual cycles in women. A clever intervention reduces patients' prolactin levels.

Pharmacotherapy for Autism Spectrum Disorder

May 20, 2021

Matthew Krause, DO

Matthew Krause, DO

Child psychiatrist with Primary Health Network, Latrobe, PA Dr. Krause has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What’s new in psychopharmacological treatment for autism? We interviewed Dr. Matthew Krause on his recent review of seven studies covering the rationale for treatment, target symptoms, the use of antipsychotics, over the counter supplements, and some new ideas in pharmacotherapy for ASD.

Antipsychotic Use Associated With Increased Risk of Mortality

March 11, 2021

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The study is not without flaws, but it raises some concerns about the long term health-effects of antipsychotic augmentation.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.